Joshua Drumm - AC Immune Head Relations
| ACIU Stock | USD 2.22 0.02 0.89% |
Insider
Joshua Drumm is Head Relations of AC Immune
| Address | Building B, Lausanne, Switzerland, 1015 |
| Phone | 41 21 345 91 21 |
| Web | https://www.acimmune.com |
AC Immune Management Efficiency
The company has return on total asset (ROA) of (0.1583) % which means that it has lost $0.1583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3731) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2025. Return On Capital Employed is likely to drop to -0.42 in 2025. At this time, AC Immune's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 18.7 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 199.4 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joan JD | Pharvaris BV | 60 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Adam Thomas | Synlogic | N/A | |
| Caroline Godfrey | PepGen | N/A | |
| Timothy MBA | Aerovate Therapeutics | 63 | |
| MD MPH | MediciNova | 56 | |
| Annie Lee | Opthea | N/A | |
| MAICD MAICD | Opthea | 48 | |
| Deepika PharmD | Pmv Pharmaceuticals | 49 | |
| Mike Zanoni | 4D Molecular Therapeutics | N/A | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Robert Fishman | 4D Molecular Therapeutics | 62 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Ian Leitch | Opthea | 61 | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Rebecca Dabora | Invivyd | 65 | |
| MBA BS | AN2 Therapeutics | 49 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 |
AC Immune Leadership Team
Elected by the shareholders, the AC Immune's board of directors comprises two types of representatives: AC Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACIU. The board's role is to monitor AC Immune's management team and ensure that shareholders' interests are well served. AC Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AC Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nuno MD, Chief Officer | ||
| Christopher Roberts, Interim Fin | ||
| Mark Danton, Executive Intelligence | ||
| Sonia Poli, Head Science | ||
| Oliver MD, VP Development | ||
| Matthias Maurer, SVP Counsel | ||
| Piergiorgio Donati, Chief Officer | ||
| Julian Snow, VP Development | ||
| Anke MD, Chief Officer | ||
| Pr MD, Chief Officer | ||
| Joshua Drumm, Head Relations | ||
| JeanFabien Monin, Chief Administrative Officer | ||
| Howard Donovan, Chief Officer | ||
| Alexandre Caratsch, General Counsel | ||
| Gary Waanders, Senior Communications | ||
| Andrea Pfeifer, CEO CoFounder | ||
| Marie KoscoVilbois, Chief Officer | ||
| Julien Rongere, Senior Assurance | ||
| Judith Moore, Global Communications | ||
| Madiha Derouazi, Chief Officer | ||
| Joseph Wettstein, Head Officer | ||
| David Hickman, Head SME |
ACIU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AC Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (16.37) % | ||||
| Current Valuation | 34.27 M | ||||
| Shares Outstanding | 100.41 M | ||||
| Shares Owned By Insiders | 38.00 % | ||||
| Shares Owned By Institutions | 27.54 % | ||||
| Number Of Shares Shorted | 1.16 M | ||||
| Price To Earning | (16.96) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.